Home » Health » Long survivors after immunotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer.

Long survivors after immunotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer.

Categories of data used

The personal health data that you use relates to the following characteristics of the beneficiaries:

Method elements

The aim of our study is to retrospectively evaluate so-called “long survivors” (LS) patients, defined by a survival greater than one year after the start of immunotherapy, in a population of patients with BC and taken into account. load successively and homogeneously in a general pulmonology department over a period of 5 years and to try to characterize these patients from a clinical, histological and biological point of view.

Population concerned

Characterizations of patients with locally advanced or metastatic long-responder non-small cell lung cancer after clinically, histologically and biologically immunotherapy

Regulatory information

Data recipient (s)

Not specified

Duration of data retention for the purposes of the project

2

Regulatory framework


Reference methodology

Authorization number / MR: 004



Existence of automated decision making

Not specified

Legal basis

(1) (e) performance of a mission of public interest (2) (j) archives, scientific or historical research, or statistics

Transfer guarantees

Not specified

Sensitive variables used

Date of death (if applicable)


Rights of individuals

Patient information is sent to living patients informing them of their various rights and allowing them to oppose the use of their data.

The records of deceased patients will be reviewed to ensure that no objection to the use of their data has been expressed by patients who are alive.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.